Navigating the Evolving Landscape of Biosimilars: Safety, Efficacy, and Regulatory Advances (2024–2025)

Biologics have transformed the treatment of chronic and life-threatening diseases, but their high cost remains a barrier to equitable access worldwide. Biosimilars—highly similar versions of approved biologics—offer a pathway to cost reduction and improved healthcare access. Over the last decade, and particularly in 2024–2025, biosimilars have experienced rapid regulatory, clinical, and market expansion. This review critically examines the scientific foundations of biosimilarity, regulatory advances, clinical evidence of safety and efficacy, and market adoption trends, with a special focus on India. Analytical comparability, pharmacokinetics, immunogenicity, and switching studies consistently demonstrate no clinically meaningful differences between biosimilars and their reference biologics. The European Medicines Agency (EMA) and U.S. FDA have advanced regulatory science by recognizing interchangeability and refining requirements, while India has emerged as a leader among developing nations, approving more than 120 biosimilars. Market data highlight substantial price erosion—ranging from 20% to 70%—across therapeutic areas, improving patient access to oncology, autoimmune, and diabetes treatments. Pharmacovigilance systems, including India’s PvPI, ensure long-term safety monitoring. Despite barriers such as prescriber hesitation and limited awareness, biosimilars are positioned to reshape global healthcare systems by 2030. This article synthesizes data, real-world evidence, and regulatory milestones to provide a comprehensive perspective on the evolving landscape of biosimilars.